LLY - Eli Lilly presents updated data on cancer medication

2023-12-12 07:21:29 ET

Eli Lilly ( NYSE: LLY ) announced on Monday updated clinical data from a global trial of its anticancer medication, pirtobrutinib.

Earlier this year, pirtobrutinib was approved under the FDA's accelerated approval pathway as Jaypirca (pirtobrutinib) to treat adult patients with relapsed or refractory MCL after at least two lines of systemic therapy. The drug also received accelerated approval to treat adult patients with CLL/SLL who have received at least two prior lines of therapy.

The latest data, presented at the 65th American Society of Hematology meet, support the role of pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).

An oral presentation detailed updated, long-term follow-up data in patients with CLL/SLL. This data set consisted of 282 patients who had received a prior Bruton's tyrosine kinase inhibitor.

Efficacy results in this cohort showed an overall response rate, including partial response with lymphocytosis (PR-L), of 81.6% (95% CI: 76.5, 85.9) for patients treated with pirtobrutinib.

With a median follow-up of 27.5 months, median progression-free survival (PFS) was 19.4 months (95% CI: 16.6, 22.1). With a median follow-up of 29.3 months, median overall survival (OS) was not estimable.

In case of MCL, patients treated with pirtobrutinib showed overall response rate of 49.3%, including 15.8% complete responses (n=24) and 33.6% partial responses (n=51). Median PFS and OS were 5.6 months and 23.5 months, respectively.

More on etc.

• Amcor: Hard To Ignore The 5% Dividend Yield
• Who's Ready For A Santa Claus REIT Rally?
• Petrobras' 5-Year Plan Highlights The Investment Opportunity
• Choice Hotels starts hostile takeover bid for Wyndham Hotels & Resorts
• Pfizer to close Seagen buyout this week as regulatory reviews complete

For further details see: